Viral factors influencing the outcome of human cytomegalovirus infection in liver transplant recipients

Journal of Clinical Virology

Volumn 51, Issue 4, 2011, Pages 229-233

  Scott, G M ^a,b   Naing, Z ^a,b   Pavlovic, J ^c   Iwasenko, J M ^a,b   Angus, P ^c   Jones, R ^c   Rawlinson, W D ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c AUSTIN HEALTH   (Australia)

Author keywords

Antiviral agents; Cytomegalovirus; Liver transplantation; Prophylaxis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; FOSCARNET; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; VALGANCICLOVIR; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; DRUG DOSE REDUCTION; DRUG EFFICACY; GENOTYPE; GRAFT RECIPIENT; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; INFECTION PREVENTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MIXED INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; VIRUS LOAD; VIRUS STRAIN;

EID: 79960063027     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.05.012     Document Type: Article

References (41)

1. Emery V.C., Cope A.V., Sabin C.A., Burroughs A.K., Rolles K., Lazzarotto T., et al. Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation. Journal of Infectious Diseases 2000, 182:1610-1615.
2. Halme L, Hockerstedt K., Lautenschlager I. Cytomegalovirus infection and development of biliary complications after liver transplantation. Transplantation 2003, 75:1853-1858.
3. Lautenschlager I., Halme L., Hockerstedt K., Krogerus L., Taskinen E. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transplant Infectious Disease 2006, 8:21-30.
4. Limaye A.P., Bakthavatsalam R., Kim H.W., Kuhr C.S., Halldorson J.B., Healey P.J., et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004, 78:1390-1396.
5. La Rosa C., Limaye A.P., Krishnan A., Longmate J., Diamond D.J. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. Journal of Infectious Diseases 2007, 195:633-644.
6. Emery V.C., Sabin C.A., Cope A.V., Gor D., Hassan-Walker A.F., Griffiths P.D. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000, 355:2032-2036.
7. Limaye A.P., Corey L., Koelle D.M., Davis C.L., Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000, 356:645-649.
8. Eid A.J., Arthurs S.K., Deziel P.J., Wilhelm M.P., Razonable R.R. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clinical Transplantation 2008, 22:162-170.
9. Lautenschlager I. CMV infection, diagnosis and antiviral strategies after liver transplantation. Transplant International 2009, 22:1031-1040.
10. Rosen H.R., Corless C.L., Rabkin J., Chou S. Association of cytomegalovirus genotype with graft rejection after liver transplantation. Transplantation 1998, 66:1627-1631.
11. Puchhammer-Stockl E., Gorzer I., Zoufaly A., Jaksch P., Bauer C.C., Klepetko W., et al. Emergence of multiple cytomegalovirus strains in blood and lung of lung transplant recipients. Transplantation 2006, 81:187-194.
12. Gorzer I., Guelly C., Trajanoski S., Puchhammer-Stockl E. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time. Journal of Virology 2010, 84:7195-7203.
13. Griffiths P.D., Ait-Khaled M., Bearcroft C.P., Clark D.A., Quaglia A., Davies S.E., et al. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus. Journal of Medical Virology 1999, 59:496-501.
14. Thomasini R.L., Sampaio A.M., Bonon S.H., Boin I.F., Leonardi L.S., Leonardi M., et al. Detection and monitoring of human herpesvirus 7 in adult liver transplant patients: impact on clinical course and association with cytomegalovirus. Transplantation Proceedings 2007, 39:1537-1539.
15. Emery V.C., Hassan-Walker A.F., Burroughs A.K., Griffiths P.D. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. Journal of Infectious Diseases 2002, 185:1723-1728.
16. Brady R.L., Green K., Frei C., Maxwell P. Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients. Transplant Infectious Disease 2009, 11:106-111.
17. Park J.M., Lake K.D., Arenas J.D., Fontana R.J. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transplantation 2006, 12:112-116. [erratum appears in Liver Transpl 2006 March;12(3):494].
18. Singh N., Wannstedt C., Keyes L., Mayher D., Tickerhoof L., Akoad M., et al. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Liver Transplantation 2008, 14:240-244.
19. Seehofer D., Rayes N., Neumann U.P., Meisel H., Oettle H., Nussler N.C., et al. Changing impact of cytomegalovirus in liver transplantation-a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis. Transplant International 2005, 18:941-948.
20. Gerna G., Lilleri D., Callegaro A., Goglio A., Cortese S., Stroppa P., et al. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation. Transplantation 2008, 86:163-166.
21. Shah T., Lai W.K., Mutimer D. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors. Transplant Infectious Disease 2005, 7:57-62.
22. Wiltshire H., Paya C.V., Pescovitz M.D., Humar A., Dominguez E., Washburn K., et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005, 79:1477-1483.
23. Jacobson M.A. Ganciclovir therapy for severe cytomegalovirus infection in immunocompetent patients. Clinical Infectious Diseases 1997, 25:1487-1488.
24. Iwasenko J.M., Scott G.M., Zeigler J., Rawlinson W.D. Emergence and persistence of multiple antiviral-resistant CMV strains in a highly immunocompromised child. Journal of Clinical Virology 2007, 40:152-155.
25. Seehofer D., Meisel H., Rayes N., Stein A., Langrehr J.M., Settmacher U., et al. Prospective evaluation of the clinical utility of different methods for the detection of human cytomegalovirus disease after liver transplantation. American Journal of Transplantation 2004, 4:1331-1337.
26. Jain A., Orloff M., Kashyap R., Lansing K., Betts R., Mohanka R., et al. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?. Transplantation Proceedings 2005, 37:3182-3186.
27. Limaye A.P., Raghu G., Koelle D.M., Ferrenberg J., Huang M.L., Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. Journal of Infectious Diseases 2002, 185:20-27.
28. Bhorade S.M., Lurain N.S., Jordan A., Leischner J., Villanueva J., Durazo R., et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. Journal of Heart and Lung Transplantation 2002, 21:1274-1282.
29. Iwasenko J.M., Scott G.M., Naing Z., Glanville A.R., Rawlinson W.D. Diversity of antiviral resistant human cytomegalovirus in heart and lung transplant recipients. Transplant Infectious Disease 2011, 13:145-153.
30. Boutolleau D., Deback C., Bressollette-Bodin C., Varnous S., Dhedin N., Barrou B., et al. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antiviral Research 2009, 81:174-179.
31. Schaffer K., Moran J., Duffy M., McCormick A.P., Hall W.W., Hassan J. Kinetics of host immune responses and cytomegalovirus resistance in a liver transplant patient. Liver Transplantation 2009, 15:1199-1203.
32. Halwachs-Baumann G., Wilders-Truschnig M., Enzinger G., Eibl M., Linkesch W., Dornbusch H.J., et al. Cytomegalovirus diagnosis in renal and bone marrow transplant recipients: the impact of molecular assays. Journal of Clinical Virology 2001, 20:49-57.
33. Munro S.C., Hall B., Whybin L.R., Leader L., Robertson P., Maine G.T., et al. Diagnosis of and screening for cytomegalovirus infection in pregnant women. Journal of Clinical Microbiology 2005, 43:4713-4718.
34. Tarrago D., Quereda C., Tenorio A. Different cytomegalovirus glycoprotein B genotype distribution in serum and cerebrospinal fluid specimens determined by a novel multiplex nested PCR. Journal of Clinical Microbiology 2003, 41:2872-2877.
35. Scott G.M., Isaacs M.A., Zeng F., Kesson A.M., Rawlinson W.D. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. Journal of Medical Virology 2004, 74:85-93.
36. McIver C.J., Jacques C.F.H., Chow S.S.W., Munro S.C., Scott G.M., Roberts J.A., et al. Development of multiplex PCRs for detection of common viral pathogens and agents of congenital infections. Journal of Clinical Microbiology 2005, 43:5102-5110.
37. Manichanh C., Olivier-Aubron C., Lagarde J.P., Aubin J.T., Bossi P., Gautheret-Dejean A., et al. Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo. Journal of General Virology 2001, 82:2767-2776.
38. Arthurs S.K., Eid A.J., Pedersen R.A., Dierkhising R.A., Kremers W.K., Patel R., et al. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transplantation 2007, 13:1703-1709.
39. Shiley K.T., Gasink L.B., Barton T.D., Pfeiffenberger P., Olthoff K.M., Blumberg E.A. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis. Liver Transplantation 2009, 15:963-967.
40. Kumar D., Chernenko S., Moussa G., Cobos I., Manuel O., Preiksaitis J., et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. American Journal of Transplantation 2009, 9:1214-1222.
41. Nebbia G., Mattes F.M., Smith C., Hainsworth E., Kopycinski J., Burroughs A., et al. Polyfunctional cytomegalovirus-specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. American Journal of Transplantation 2008, 8:2590-2599.